KMT2D and acute myeloid leukemia: Further, we found that there was little difference in the KMT2D‐binding, H3K4me1, or H3K4me2 levels between Kmt2d knockdown and restored AML cells in Pol I or III binding sites (Figure S4F, Supporting Information).